EUVIMEDDescoperă EUVIMED
Open access · CC BY-NC 4.0

In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers

Mathias Lemarchand, Kiefer Thouin, Thiéry De Serres-Bérard iD, Sabrina Bellenfant, Sébastien Cadau, François Berthod iD

Biotechnology and Bioengineering · 2023

DOI: 10.1002/bit.28359 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2023. Written by Mathias Lemarchand and 5 co-authors. Institution: LOEX, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada. Major MEDLINE topics: Diabetic Foot, Diabetes Mellitus. Cited 16 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: CIHR, Canadian Institutes of Health Research.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Diabetic foot ulcers are a major complication of diabetes that occurs following minor trauma. Diabetes‐induced hyperglycemia is a leading factor inducing ulcer formation and manifests notably through the accumulation of advanced glycation end‐products (AGEs) such as N‐carboxymethyl‐lysin. AGEs have a negative impact on angiogenesis, innervation, and reepithelialization causing minor wounds to evolve into chronic ulcers which increases the risks of lower limb amputation. However, the impact of AGEs on wound healing is difficult to model (both in vitro on cells, and in vivo in animals) because it involves a long‐term toxic effect. We have developed a tissue‐engineered wound healing model made of human keratinocytes, fibroblasts, and endothelial cells cultured in a collagen sponge biomaterial. To mimic the deleterious effects induced by glycation on skin wound healing, the model was treated with 300 µM of glyoxal for 15 days to promote AGEs formation. Glyoxal treatment induced carboxymethyl‐lysin accumulation and delayed wound closure in the skin mimicking diabetic ulcers. Moreover, this effect was reversed by the addition of aminoguanidine, an inhibitor of AGEs formation. This in vitro diabetic wound healing model could be a great tool for the screening of new molecules to improve the treatment of diabetic ulcers by preventing glycation.

Subjects

MeSH terms (MEDLINE)

Diabetic FootDiabetes MellitusAnimalsHumansMaillard ReactionEndothelial CellsWound HealingGlycation End Products, AdvancedGlyoxal

Author keywords

AGEdiabetesglycationkeratinocytestissue engineeringwound healing

Substances

Glycation End Products, AdvancedGlyoxal

Authors and institutions

  • LOEX, Centre de recherche du CHU de Québec-Université Laval, Québec, Canada.
  • Département de Chirurgie, Faculté de Médecine, Université Laval, Québec, Canada.

ORCID profiles: Thiéry De Serres-Bérard, François Berthod

Funding

  • CIHR
  • Canadian Institutes of Health Research

Cite

APA

Lemarchand, M., Thouin, K., De Serres-Bérard, T., Bellenfant, S., Cadau, S., & Berthod, F. (2023). In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28359

Vancouver

Lemarchand M, Thouin K, De Serres-Bérard T, Bellenfant S, Cadau S, Berthod F. In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers. Biotechnology and Bioengineering. 2023. doi:10.1002/bit.28359

BibTeX
@article{Lemarchand2023,
  author = {Lemarchand, Mathias and Thouin, Kiefer and De Serres-Bérard, Thiéry and Bellenfant, Sabrina and Cadau, Sébastien and Berthod, François},
  title = {In vitro glycation of a tissue‐engineered wound healing model to mimic diabetic ulcers},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  doi = {10.1002/bit.28359}
}
Start for free →